Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Debt: 2011-2024

Historic Total Debt for Ani Pharmaceuticals (ANIP) over the last 11 years, with Dec 2024 value amounting to $318.3 million.

  • Ani Pharmaceuticals' Total Debt fell 2.23% to $312.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $312.9 million, marking a year-over-year decrease of 2.23%. This contributed to the annual value of $318.3 million for FY2024, which is 7.13% up from last year.
  • According to the latest figures from FY2024, Ani Pharmaceuticals' Total Debt is $318.3 million, which was up 7.13% from $297.1 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Total Debt high stood at $318.3 million for FY2024, and its period low was $185.7 million during FY2020.
  • Over the past 3 years, Ani Pharmaceuticals' median Total Debt value was $297.1 million (recorded in 2023), while the average stood at $300.6 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Total Debt skyrocketed by 54.76% in 2021 and then declined by 0.30% in 2022.
  • Ani Pharmaceuticals' Total Debt (Yearly) stood at $185.7 million in 2020, then skyrocketed by 54.76% to $287.4 million in 2021, then fell by 0.30% to $286.5 million in 2022, then rose by 3.69% to $297.1 million in 2023, then climbed by 7.13% to $318.3 million in 2024.